stockrow
Friday 6 November 2026
Export GRAL’s income statement to Excel — free account
GRAIL, Inc.
GRAL Healthcare Diagnostics & Research
GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.
- Revenue
- +3.71%
- EPS
- +10.2%
- Free cash flow
- −24.9%
Quarter to September 2026, against a year earlier
124.40
19.26
−13.41%
Follow GRAL
Alert me
GRAIL, Inc. (GRAL) Operating margin
GRAIL, Inc.'s operating margin over the twelve months to 30 September 2026 was −347.3%, up 34.7 percentage points from fiscal 2025 (−382.0%). That is below the Diagnostics & Research industry median of −5.68% and below the Healthcare sector median of 0.00%.
Operating margin, annual
Embed this chart
Annual newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| FY2025 | −382.0% | 1,361.05 |
| FY2024 | −1,743.0% | (115.42) |
| FY2023 | −1,627.6% | 8,170.57 |
| FY2022 | −9,798.2% | — |
Quarterly newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| Sep 2026 | −385.3% | 3.60 |
| Jun 2026 | −388.9% | (56.01) |
| Mar 2026 | −332.9% | (47.51) |
| Dec 2025 | −285.4% | 60.80 |
| 9 more quarters | Free account |
Operating margin against peers
| Company | Operating margin |
|---|---|
| SHC Sotera Health Company compare | 32.7% |
| CDNA CareDx, Inc. compare | 23.4% |
| QGEN QIAGEN N.V. compare | 21.2% |
| VCYT Veracyte, Inc. compare | 17.1% |
| BLLN BillionToOne, Inc. compare | 10.2% |
| ICLR ICON PLC compare | 8.72% |
| RDNT RadNet, Inc. compare | 3.12% |
| ADPT Adaptive Biotechnologies Corporation compare | −16.2% |
| GRAL GRAIL, Inc. | −347.3% |
| Diagnostics & Research industry median | −5.68% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Operating margin is
EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.
EBIT ÷ Revenue
More on GRAL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement